Currents in Contemporary Ethics for Asians Only? The Perils of Ancestry-Based Drug Prescribing

Abrahams E. Ginsburg G. S. Silver M. , “The Personalized Medicine Coalition: Goals and Strategies,” American Journal of PharmacoGenomics 5, no. 6 (2005): 345–355; Lewis L. D. , “Personalized Drug Therapy; The Genome, The Chip and the Physician,” British Journal of Clinical Pharmacology 60, no. 1 (2005): 1–4.

U.S. Food and Drug Administration Center for Drug Evaluation and Research, Information for Healthcare Professionals: Carbamazepine (Marketed as Carbatrol, Equetro, Tegretol, and Generics) - FDA Alert, available at <http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm> (last visited June 23, 2008) [hereinafter cited as USDA); Dooren J. C. Goldstein J. , “Epilepsy Drug to Get Stronger Warning,” Wall Street Journal (Eastern Edition), December 13, 2007, at D4.

Id. (USDA).

Alfirevic A. Jorgensen A. L. Williamson P. R. Chadwick D. W. Park B. K. Pirmohamed M. , “HLA-B Locus in Caucasian Patients with Carbamazepine Hypersensitivity,” Pharmacogenomics 7, no. 6 (2006): 813–818; Hung S. I. Chung W. H. Jee S. H. Chen W. C. Chang Y. T. Lee W. R. Hu S. L. Wu M. T. Chen G. S. Wong T. W. Hsiao P. F. Chen W. H. Shih H. Y. Fang W. H. Wei C. Y. Lou Y. H. Huang Y. L. Lin J. J. Chen Y. T. , “Genetic Susceptibility to Carbamazepine-Induced Cutaneous Adverse Drug Reactions,” Pharmacogenetics and Genomics 16, no. 4 (2006): 297–306; Lonjou C. Thomas L. Borot N. Ledger N. de Toma C. LeLouet H. Graf E. Schumacher M. Hovnanian A. Mockenhaupt M. Roujeau J. C. , “A Marker for Stevens-Johnson Syndrome…: Ethnicity Matters,” Pharmacogenomics Journal 6, no. 4 (2006): 265–268; Man C. B. L. Kwan P. Baum L. Yu E. Lau K. M. Cheng A. S. H. Ng M. H. L. , “Association between HLA-B*1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese,” Epilepsia 48, no. 5 (2007): 1015–1018; Chung W. H. Hung S. I. Hong H. S. Hsih M. S. Yang L. C. Ho H. C. Wu J. Y. Chen Y. T. , “Medical Genetics: A Marker for Stevens-Johnson Syndrome,” Nature 428, no. 6982 (2004): 486.

See USDA, supra note 2.

See generally Veregin H. , ed., Goode's Atlas of Asia (New Jersey: John Wiley & Sons, 2004).

See USDA, supra note 2.

U.S. Food and Drug Administration, FDA News, FDA Approves BiDil Heart Failure Drug for Black Patients, available at <http://www.fda.gov/bbs/topics/news/2005/new01190.html> (last visited June 23, 2008).

Stewart A. , “Heart Drug's Racial Focus Proves a Liability Rather Than an Asset,” The Star Ledger, May 31, 2008, available at <http://www.nj.com/business/index.ssf/2008/05/heart_drugs_racial_focus_prove.html> (last visited June 23, 2008); Kahn J. , “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy Law 4, no. 1 (2004): 1–46; Armstrong D. , “Home and Family: NitroMed Halts Sale of Drug,” Wall Street Journal (Eastern Edition), January 16, 2008, at D3.